CASI Pharmaceuticals, Inc.
Develops and commercializes drugs for oncology, transplant, and autoimmune disease.
CASI | US
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 1701-1702, CHINA CENTRAL OFFICE TOWER 1, 100025 BEIJING
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics. The company's primary clinical development program centers on CID-103, an investigational anti-CD38 monoclonal antibody. This therapy is being developed to treat antibody-mediated rejection (AMR) in organ transplant recipients and for various autoimmune diseases, addressing a significant unmet medical need. In addition to its research and development pipeline, CASI maintains a portfolio of commercialized pharmaceutical products, primarily targeting the oncology market.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all CASI Pharmaceuticals, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for CASI Pharmaceuticals, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for CASI Pharmaceuticals, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
%20Ltd/other/HUTCHMED_China_Ltd-logo.png){kind=logo}
